Vaccinating the world’s population quickly in a pandemic has enormous health and economic benefits. We analyze the problem faced by governments in determining the scale and structure of procurement for vaccines. We analyze alternative approaches to procurement, arguing that buyers should directly fund manufacturing capacity and shoulder most of the risk of failure, while maintaining some direct incentives for speed. We analyzed the optimal portfolio of vaccine investments for countries with different characteristics as well as the implications for international cooperation. Our analysis, considered in light of the experience of 2020, suggests lessons for future pandemics. 

More on this topic

BFI Working Paper·Oct 12, 2026

Gains from Trade in Gun Policy: A Compensation-Based Benchmark

Brad Shapiro, Sara Drango, and Sarah Moshary
Topics: Fiscal Studies, Health care
BFI Working Paper·Oct 6, 2026

Provider and Worker Responses to Supply-Side Audits in Social Insurance

Pablo A. Celhay, Nicolás Figueroa, Carla Guadalupi, and Benjamín Oteíza
Topics: Health care
BFI Working Paper·Sep 28, 2026

Crime in Covid Times

Jens Ludwig
Topics: COVID-19